Growing Calls For Labelling Changes With Obesity Patients In Mind

03 Feb 2025

• By Ed Silverman

Despite significant investments in weight loss treatments, pharmaceutical companies face criticism for neglecting to study their drugs in obese patients, possibly leading to incomplete labeling and patient risks, prompting calls for the FDA to enforce more inclusive clinical trials and updated drug information.

Key Takeaways

Advocates and academics argue that many existing medications lack proper labeling for people with obesity, leading to potential patient harm and ineffective care. They are urging the FDA to require pharma companies to include obese individuals in clinical trials and update product labels accordingly.

As the pharmaceutical industry invests more money than ever before to develop new weight loss treatments, a growing number of...